Denali Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating
Analyst Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at ...
Denali Gains 26.6% in a Year: How Should You Play the Stock?
DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.
Denali Therapeutics’ (DNLI) Outperform Rating Reiterated at William Blair
William Blair reaffirmed their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report ...
ETF Daily News5d
Denali Therapeutics Inc. (NASDAQ:DNLI) Sees Significant Increase in Short Interest
Denali Therapeutics stock opened at $21.93 on Monday. The firm’s 50 day moving average price is $23.13 and its 200-day moving average price is $24.79. Denali Therapeutics has a 1 year low of $14 ...
Nasdaq3d
Denali Gains 26.6% in a Year: How Should You Play the Stock?
Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained 26.6% against the industry’s decline of 14.3%. The stock has also ...
Nasdaq3d
DNLI Makes Bullish Cross Above Critical Moving Average
In trading on Tuesday, shares of Denali Therapeutics Inc (Symbol: DNLI) crossed above their 200 day moving average of $23.11, changing hands as high as $23.33 per share. Denali Therapeutics Inc ...
BioSpace1d
FDA Tacks Boxed Warning on Teva’s Copaxone, Other MS Drugs
The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...